We describe four prenatal diagnoses in a family with autosomal dominant polycystic kidney disease. Two pregnancies were terminated following the detection of enlarged echogenic fetal kidneys with cysts. Histopathological examination confirmed the diagnosis of polycystic kidney disease. Linkage to PKD1 was obtained by the analysis of DNA from relatives in three generations and from paraffin blocks and formalin fixed fetal tissues. Prenatal DNA analysis in subsequent pregnancies identified one unaffected fetus and one fetus carrying the high risk PKDl allelle. Information on survival and subsequent outcome of PKD cases presenting in utero was requested by this family before prenatal testing was performed.
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder characterised by progressive renal cyst development, hypertension, and frequently by the development of end stage renal failure (ESRF).
ADPKD is genetically heterogeneous; the PKD1 gene has been localised at l6p 13.3,' the PKD2 gene at 4ql3-23,2 and the PKD3 locus remains unknown.3 PKD1 shows wide phenotypic variability which includes clinical presentation in utero. The mechanism for such early and severe expression of the disease is at present unknown, but it could include segregation of a modifying gene with inefficient DNA transcription/repair function contributed by the unaffected parent. This hypothesis is supported by the report of the same nonsense PKD 1 mutation in a father and affected fetus,4 the two hit mechanism for renal cyst formation recently reported by Qian et al,' by the approximately 25% recurrence rate for similarly affected sibs,6 and by the low incidence of fetal presentation reported in second degree relatives in these families. 7 8 We describe a PKD1 family, where the gene carrier father had two unilateral renal cysts at the age of 37, but two of his offspring developed renal cysts in utero. In these ADPKD families, following a diagnosis of fetal/early childhood presentation of renal cysts, prenatal testing or screening will be requested in subsequent pregnancies. Regular follow up of affected children will be necessary as the onset of complications of the disease occur early. 11 families followed for a mean of five years. From 24 children diagnosed prenatally or up to 1 year of life, eight remained well (mean age of these children was 3.2 years, range 3 months to 7 years). Sixteen of 24 developed hypertension requiring treatment (at a mean age of 2.9 years, ranging from birth to 12 years; six of 16 were below the age of 6 years). ESRF developed in three hypertensive children (at a mean age of 2.8 years, range 1 to 4 years). Complications of PKD were therefore present in 67% of survivors at a mean age of 3 years.
Discussion
In this report we have shown that archival material from affected fetuses can be used for linkage analysis despite extensive DNA degradation. Since no common mutations have yet been found for PKD 1, and duplication of the 5' part of the gene occurs more proximally on 16p,'5 mutation detection is at present difficult and determination of the disease locus in a family relies on genetic linkage analysis.
Linkage to the PKD2 region was not evaluated in this family. In non-PKD1 families, the onset of renal failure is later than in PKD 18 and all families with ADPKD diagnosed in utero analysed to date have shown linkage to PKID1.'7 19 20 The probability of linkage between the intragenic PKD1 marker KG8 and the disease in this family was 0.978 to 0.995, which was statistically unlikely to be the result of chance. For these reasons, prenatal diagnosis by DNA was considered reliable and was offered.
Severe infantile PKD has been attributed to large deletions involving both the PKD1 gene and the adjacent tuberous sclerosis gene, TSC2.) Since these genes show tail to tail orientation and KG8 shows heterozygosity in the affected subjects reported here, a contiguous gene deletion is highly unlikely in this family.
In ADPKD, the incidence of development of renal cysts in utero has been estimated as 2%.'
The recurrence risk is high, with 45% of gene carrier sibs (or 25% of all sibs) showing comparable early manifestation.6 Before prenatal DNA diagnosis in this family, the parents had to make a decision whether to terminate an affected pregnancy without knowledge of the severity of the disease in the fetus. As two affected cases with in utero presentation have already occurred and the recurrence risk was 45%, the parents have made the difficult decision to terminate the subsequent affected fetus. The possible mechanisms of severe and much earlier clinical presentation of ADPKD in the fetus than in the parent are of great interest. These include anticipation, imprinting, and the segregation of modifying genes. 8 22 Suggestive, but not conclusive data are available for anticipation and imprinting in ADPKD.23-2' Evidence for the former was presented by Fick et al,2" who found that of 86 informative ADPKD families, 53% showed 10 years earlier onset of ESRF in offspring, when compared to their affected parent. The clinical presentation of ADPKD in the family presented here would be difficult to reconcile with anticipation. The affected relative in generation I showed more severe clinical symptoms than his offspring in generation II, while the affected father of the cases presenting in utero was asymptomatic. The possibility of imprinting is supported by the findings of statistically significant (p<0.05) maternal transmission found in fetal/early childhood ADPKD onset cases (M:F 23:41) and significantly earlier onset of ESRF in subjects with ADPKD1 inheriting the disease from their mother rather than from their father (50.5 v 64.8 years, p= 0.004).25 However, in the family reported here, the transmission was paternal. No anticipation has been observed in many families with in utero onset of the disease, which is illustrated by the family reported here and by others. '7 26 It is of interest to examine the high recurrence risk for in utero presentation of PKD 1, with the recent data from Qian et al. ' The authors showed that renal cysts in ADPKD are monoclonal, they have shown loss of heterozygosity for two intragenic PKD 1 markers within individual cysts, and confirmed the loss of the normal allelle. Their report provides convincing data for a two hit mechanism in the formation of renal cysts, the same mechanism which results in loss of function in tumour suppressor genes. If this is the case, the segregation of a rare gene with inefficient DNA transcription/ repair from the unaffected parent could produce a high frequency of somatic second hits and multiple renal cysts in utero 
